Company intelligence

PCRX

Pacira BioSciences, Inc. · NASDAQ · Healthcare

Price$36.31-0.22% · −$0.08

Market cap1.43BEquity value

P / E14.0Trailing ratio

Volume4.69MLatest session

Market data

PCRX price chart

TradingView

Related signals

1 min delayed

Browse public PCRX signals with their source context and measured market impact. Open any signal for its permanent analysis page.

PCRXOct 8, 2026-0.22% since signal

Pacira Faces Fiduciary Investigation Tied to Viatris Cash Acquisition

Pacira BioSciences' board is under a securities-litigation probe by Brodsky & Smith over the Viatris sale at $36.50 per share, valuing the deal at $1.65 billion. The investigation questions whether the process was fair and whether shareholders were adequately served. A material impact would hinge on deal closure timing and potential renegotiation outcomes.

View signal analysis

PCRXOct 8, 2026+44.12% since signal

Viatris to Acquire Pacira Biosciences for $1.65 Billion in Pain Therapy Expansion

Viatris has agreed to acquire Pacira Biosciences for $1.65 billion, adding Pacira’s pain-therapy products to its portfolio. The deal signals a strategic exit for Pacira and provides an immediate premium to shareholders, with closing contingent on regulatory approvals. The transaction could reshape PCRX’s near-term value and reduce Pacira’s standalone growth risk for Viatris.

View signal analysis

PCRXApr 8, 2025-1.24% since signal

Pacira Settles Patent Dispute Over Exparel With Fresenius, Delays Pain Med' Generics Entry Until 2030, Stock Jumps

PCRX settled litigations regarding Exparel patents with multiple pharmaceutical companies. Settlement includes a license for limited generic entry beginning in early 2030. Pacira’s fourth-quarter sales for Exparel increased 3% year-over-year to $147.7 million. Analysts maintain 'Buy' ratings with price targets raised significantly after the news. PCRX stock rose 16.8%, reflecting positive market sentiment on this announcement.

View signal analysis

Research